The document outlines a machine learning-based application, Detect-All, designed to revolutionize the detection and treatment of acute lymphoblastic leukemia (ALL) with enhanced accuracy and accessibility. It aims to provide personalized treatment options by analyzing blood samples, achieving a 94% accuracy rate, and is integrated with advanced data visualization techniques. The market for leukemia diagnostics is projected to grow significantly, highlighting the importance and potential of this innovative technology.